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Abstract
Debate exists regarding the safety of metformin and the risk of metformin-associated lactic 
acidosis, particularly in the setting of kidney dysfunction. Data from two studies examining the 
interplay between metformin, acute kidney injury, and complications including lactic acidosis 
suggest that metformin should be used conservatively in patients with kidney dysfunction.
Biguanides are longstanding pharmacotherapeutics agents against diabetes mellitus. In early 
medieval times, Galega officinalis (also known as French lilac or goat’s-rue) was used as a 
remedy for diabetes mellitus, and in the 1920s guanidino compounds were identified in 
French lilac extracts1. Oral biguanide agents became available for the treatment of diabetes 
mellitus in the 1950s, and metformin was approved as an antidiabetic drug by the FDA in 
1995. Since then, metformin has had demonstrated efficacy in improving multiple metabolic 
end points, including insulin sensitivity, the metabolism of free fatty acids, dyslipidaemia, 
excess body fat and weight, and cardiovascular health. In a corollary study of the UK 
Prospective Diabetes Study, in which 1,704 overweight patients with diabetes mellitus were 
randomly assigned to receive conventional versus intensive therapy with metformin, insulin 
or the antidiabetic agents chlorpropamide or glibenclamide, those given metformin had a 
lower risk of myocardial infarction, all diabetes end points, diabetes-related death and 
allcause mortality than patients in other groups2. Thus, the American Diabetes Association 
and European Association for the Study of Diabetes recommend that metformin treatment is 
initiated when diabetes mellitus is diagnosed, barring no contraindications3. However, 
debate remains regarding the safety of metformin in the setting of impaired kidney function 
due to the risk of metformin-associated lactic acidosis (MALA). Two studies now examine 
metformin and the complications of acute kidney injury (AKI) and lactic acidosis in two 
well-characterized cohorts of patients with diabetes mellitus4,5.
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In the 1970s, phenformin and buformin (antidiabetic drugs of the biguanide class) were 
withdrawn from the market in most countries due to complications of life-threatening lactic 
acidosis1. Although the frequency of lactic acidosis due to metformin is comparatively lower 
than that of phenformin, metformin use is restricted in kidney disease given the risk of 
MALA. In individuals with normal kidney function, metformin is filtered from the 
glomerulus and secreted from the proximal tubule in a non-metabolized and non-protein 
bound form, but its clearance decreases by 75% when estimated glomerular filtration 
(eGFR) falls to 30–59 ml/min/1.73 m2 (REF. 6). The accumulation of metformin and the 
associated toxicity impairs mitochondrial function and oxygen consumption and diminishes 
gluconeogenesis and glycogenolysis, leading to the generation of lactate and a non-hypoxic 
type B lactic acidosis1. Whereas AKI is a key precipitant of MALA in patients on stable 
metformin therapy, sparse epidemiologic data exists on the inter-relationships between 
metformin use, AKI and lactic acidosis.
To address this gap in knowledge, Connelly et al. conducted a case-control study of 1,746 
participants with type 2 diabetes mellitus and 846 individuals without diabetes, all of whom 
underwent lactate measurement between 1994 and 2014 in Tayside, Scotland5. Using the 
Genetics of Diabetes Audit and Research Tayside (GoDARTs) cohort, cases of lactic 
acidosis were defined as those with lactate >5 mmol/l and serum bicarbonate <18 mmol/l; 
controls were defined as those in the remaining source population with normal lactate levels; 
metformin users were defined as individuals who recieved a metformin prescription within 3 
months prior to lactate measurement. Using mixed effects logistic regression models, the 
investigators observed a 2.3-fold higher risk of lactic acidosis among metformin users versus 
non-users. The presence of AKI (as judged using serum creatinine criteria from the Kidney 
Disease: Improving Global Outcomes (KDIGO) guidelines) modified the metformin–lactic 
acidosis relationship; the association between these parameters increased with increased 
AKI severity. In the overall cohort, lactate concentrations were 0.34 mmol/l higher in 
metformin users versus non-users; a greater increase in lactate concentration was observed 
with increasing severity of AKI.
Bell et al. examined the interaction between metformin, AKI, and adverse outcomes in 
another cohort based in Tayside, Scotland4. By linking Health Informatics Centre electronic 
health record data from a population of ~400,000 residents in Tayside to the Scottish Care 
Initiative-Diabetes Collaboration (which includes records for 99% of patients with diabetes 
mellitus in Scotland), and to a prescription database of all community pharmacies in 
Tayside, the investigators identified 25,148 patients with type 2 diabetes mellitus for whom 
prescription data between 2004 and 2013 was available. They examined the association 
between metformin and the risk of hospital-based AKI, which was defined by creatinine-
based KDIGO criteria, with the aim of using AKI as a proxy of lactic acidosis. Using time-
updated medication data, they did not find an association between metformin and AKI. 
However, patients that had ‘ever’ used metformin had a 1.3-fold higher risk of AKI than 
those who had ‘never’ used metformin. Yet inference from these findings is limited by the 
fact that AKI is not a specific proxy for lactic acidosis, and by the lack of biochemical data 
confirming the presence of MALA. The investigators also found that metformin use versus 
no treatment at admission in patients with incident AKI was associated with a greater 28-day 
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survival. Finally, the baseline kidney function of patients predicted hospital-based AKI 
because incrementally higher rates of AKI were observed with increasingly lower eGFRs.
These two reports are timely, given recent policy-level changes in metformin regulation. The 
US FDA has relaxed its recommendations to allow metformin use in patients with mild and 
moderate kidney dysfunction (eGFR 45–59 ml/min/1.73 m2 and 30–44 ml/min/1.73 m2, 
respectively)6, and European Medicines Agency guidelines have been eased to allow 
metformin use in moderate kidney dysfunction (eGFR 30–59 ml/min/1.73 m2)4. Although 
the metformin package insert advises against its use in conditions leading to AKI (including 
cardiovascular collapse or shock, myocardial infarction and sepsis), the FDA does not 
recommend with-holding metformin in this context6. However, the UK Renal Association 
and National Health Services England advocate that metformin be discontinued in AKI-
predisposing illnesses5.
Several findings from the studies discussed suggest that metformin should be more 
conservatively used in patients with kidney dysfunction. First, Connelly et al. present 
compelling data indicating that metformin should be discontinued in AKI-predisposing 
conditions given the heightened risk of MALA. Although Bell et al. showed that metformin 
use was associated with comparatively greater survival among incident AKI cases, the 
absence of a ‘new-user’ design may not have accounted for patients who stopped using 
metformin or died due to its adverse effects before study entry, biasing results towards a 
protective effect. Second, as Bell et al. demonstrated that underlying kidney dysfunction is a 
major predictor of AKI, metformin should be prescribed with caution to patients with 
chronic kidney disease (CKD). Third, although both studies add knowledge to the field, they 
also highlight the challenges of accurately identifying MALA by epidemiologic studies 
alone. For example, Connelly et al. observed a higher crude incidence rate of lactic acidosis 
as compared with other recent studies, possibly due to selection bias as non-protocolized 
lactate measurements were obtained from clinical data whereby metformin users may have 
undergone more frequent testing. Conversely, although systematic reviews suggest that 
MALA incidence is low, this low incidence may be due to the under-representation of high-
risk populations in these studies (TABLE 1), non-sensitive and non-specific methods of 
outcome ascertainment (diagnostic codes) and residual confounding by non-indication. 
Rigorous studies, including clinical trials that examine the safety and effectiveness of 
metformin in CKD and/or other high-risk groups, should determine the eGFR threshold 
above which metformin use is safe. Meanwhile, we recommend reviewing the use of 
metformin in patients with eGFR 45–59 ml/min/1.73 m2, discontinuing its use when eGFR 
is <45 ml/min/1.73 m2, and discontinuing metformin in other AKI-predisposing conditions 
irrespective of eGFR6.
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Table 1
Metformin and the risk of lactic acidosis in patients with diabetes and CKD
Author (year) Data source (country) Study population Findings
Ekstrom et al. 
(2012)7
National Diabetes Register 
(Sweden)
Overall cohort (n = 51,675), examined 
patients stratified by eGFR
• eGFR 45–59 ml/min/1.73 m2 (n = 
6,960): metformin users at 
decreased risk of acidosis and 
serious infection
• eGFR <45 ml/min/1.73 m2 (n = 
2,044): metformin users trend 
towards an increased risk of 
acidosis and serious infection
Eppenga et al. 
(2014)8
Clinical Practice Research 
Datalink (UK)
• 223,968 metformin users
• 34,571 patients naive to 
metformin
• eGFR <60 ml/min/1.73 m2: 
metformin users had a 6.34-fold 
increase in risk of lactic acidosis
• eGFR <45 ml/min/1.73 m2: 
metformin users had a 6.74-fold 
increase in risk of lactic acidosis
• Overall incidence rate low: 7 
events per 29,751 person-years
Richy et al. 
(2014)9
Clinical Practice Research 
Datalink (UK)
77,601 metformin users • Total of 35 non-fatal lactic 
acidosis events
• Numerical trend for an increase 
in lactic acidosis events with 
eGFR <60 ml/min/1.73 m2
Hung et al. 
(2015)10
Taiwan National Health 
Insurance Research 
Database
• Patients with Stage 5 
CKD prescribed an 
erythropoietin-
stimulating agent 
(coverage was restricted 
to those with creatinine 
levels of >530 μmol/l (>6 
mg/dl))
• 813 metformin users 
matched to 2,439 non-
users using propensity 
scores
Metformin users had a 35% increase in 
mortality risk
CKD; chronic kidney disease; eGFR, estimated glomerular filtration.
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